LCZ696 improves cardiac function via alleviating Drp1-mediated mitochondrial dysfunction in mice with doxorubicin-induced dilated cardiomyopathy

Journal of Molecular and Cellular Cardiology

Volumn 108, Issue , 2017, Pages 138-148

  Xia, Yan ^a   Chen, Zhangwei ^a   Chen, Ao ^a   Fu, Mingqiang ^a   Dong, Zhen ^a   Hu, Kai ^a   Yang, Xiangdong ^a   Zou, Yunzeng ^a   Sun, Aijun ^a   Qian, Juying ^a   Ge, Junbo ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Apoptosis; Doxorubicin; Drp1; LCZ696; Mitochondrial dynamics

Indexed keywords

ADENOSINE TRIPHOSPHATE; DYNAMIN; DYNAMIN RELATED PROTEIN 1; SACUBITRIL PLUS VALSARTAN; SERINE; SODIUM CHLORIDE; UNCLASSIFIED DRUG; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; DNM1L PROTEIN, MOUSE; DOXORUBICIN; TETRAZOLE DERIVATIVE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; CARDIAC MUSCLE CELL; CASE REPORT; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DOXORUBICIN INDUCED DILATED CARDIOMYOPATHY; FEMALE; GENE OVEREXPRESSION; HEART FUNCTION; HEART PROTECTION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; MITOCHONDRIAL DYNAMICS; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; DISEASE MODEL; DRUG EFFECTS; ECHOCARDIOGRAPHY; GENE EXPRESSION; GENETICS; HEART VENTRICLE FUNCTION; METABOLISM; PATHOPHYSIOLOGY; ULTRASTRUCTURE;

AMINOBUTYRATES; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANIMALS; APOPTOSIS; CARDIOMYOPATHY, DILATED; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOXORUBICIN; DYNAMINS; ECHOCARDIOGRAPHY; FEMALE; GENE EXPRESSION; HUMANS; MALE; MICE; MITOCHONDRIA; MYOCYTES, CARDIAC; TETRAZOLES; VENTRICULAR DYSFUNCTION;

EID: 85020751260     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2017.06.003     Document Type: Article

References (34)

1. McMurray, J., Packer, M., Desai, A., Gong, J., Greenlaw, N., Lefkowitz, M., et al. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. Eur. Heart J. 36 (2015), 434–439.
2. McMurray, J.J., Packer, M., Desai, A.S., Gong, J., Lefkowitz, M.P., Rizkala, A.R., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 371 (2014), 993–1004.
3. Rosca, M.G., Hoppel, C.L., Mitochondrial dysfunction in heart failure. Heart Fail. Rev. 18 (2013), 607–622.
4. Liesa, M., Palacin, M., Zorzano, A., Mitochondrial dynamics in mammalian health and disease. Physiol. Rev. 89 (2009), 799–845.
5. Chen, L., Knowlton, A.A., Mitochondrial dynamics in heart failure. Congest Heart Fail. 17 (2011), 257–261.
6. Ong, S.B., Hausenloy, D.J., Mitochondrial morphology and cardiovascular disease. Cardiovasc. Res. 88 (2010), 16–29.
7. Green, D.R., Reed, J.C., Mitochondria and apoptosis. Science 281 (1998), 1309–1312.
8. Frank, S., Gaume, B., Bergmann-Leitner, E.S., Leitner, W.W., Robert, E.G., Catez, F., et al. The role of dynamin-related protein 1, a mediator of mitochondrial fission, in apoptosis. Dev. Cell 1 (2001), 515–525.
9. Shirihai, O.S., Song, M., Dorn, G.W. 2nd, How mitochondrial dynamism orchestrates mitophagy. Circ. Res. 116 (2015), 1835–1849.
10. Marin-Garcia, J., Akhmedov, A.T., Moe, G.W., Mitochondria in heart failure: the emerging role of mitochondrial dynamics. Heart Fail. Rev. 18 (2013), 439–456.
11. Lee, Y.J., Jeong, S.Y., Karbowski, M., Smith, C.L., Youle, R.J., Roles of the mammalian mitochondrial fission and fusion mediators Fis1, Drp1, and Opa1 in apoptosis. Mol. Biol. Cell 15 (2004), 5001–5011.
12. Murphy, E., Ardehali, H., Balaban, R.S., DiLisa, F., Dorn, G.W. 2nd, Kitsis, R.N., et al. Mitochondrial function, biology, and role in disease: a scientific statement from the American Heart Association. Circ. Res. 118 (2016), 1960–1991.
13. Chen, L., Gong, Q., Stice, J.P., Knowlton, A.A., Mitochondrial OPA1, apoptosis, and heart failure. Cardiovasc. Res. 84 (2009), 91–99.
14. Disatnik, M.H., Ferreira, J.C., Campos, J.C., Gomes, K.S., Dourado, P.M., Qi, X., et al. Acute inhibition of excessive mitochondrial fission after myocardial infarction prevents long-term cardiac dysfunction. J. Am. Heart Assoc., 2, 2013, e000461.
15. Ong, S.B., Subrayan, S., Lim, S.Y., Yellon, D.M., Davidson, S.M., Hausenloy, D.J., Inhibiting mitochondrial fission protects the heart against ischemia/reperfusion injury. Circulation 121 (2010), 2012–2022.
16. Carvalho, F.S., Burgeiro, A., Garcia, R., Moreno, A.J., Carvalho, R.A., Oliveira, P.J., Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy. Med. Res. Rev. 34 (2014), 106–135.
17. Liu, M.H., Shan, J., Li, J., Zhang, Y., Lin, X.L., Resveratrol inhibits doxorubicin-induced cardiotoxicity via sirtuin 1 activation in H9c2 cardiomyocytes. Exp. Ther. Med. 12 (2016), 1113–1118.
18. Marechal, X., Montaigne, D., Marciniak, C., Marchetti, P., Hassoun, S.M., Beauvillain, J.C., et al. Doxorubicin-induced cardiac dysfunction is attenuated by ciclosporin treatment in mice through improvements in mitochondrial bioenergetics. Clin. Sci. (Lond.) 121 (2011), 405–413.
19. Green, P.S., Leeuwenburgh, C., Mitochondrial dysfunction is an early indicator of doxorubicin-induced apoptosis. Biochim. Biophys. Acta 1588 (2002), 94–101.
20. Wang, J.X., Zhang, X.J., Feng, C., Sun, T., Wang, K., Wang, Y., et al. MicroRNA-532-3p regulates mitochondrial fission through targeting apoptosis repressor with caspase recruitment domain in doxorubicin cardiotoxicity. Cell Death Dis., 6, 2015, e1677.
21. Suematsu, Y., Miura, S., Goto, M., Matsuo, Y., Arimura, T., Kuwano, T., et al. LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice. Eur. J. Heart Fail. 18 (2016), 386–393.
22. Gao, S., Ho, D., Vatner, D.E., Vatner, S.F., Echocardiography in mice. Curr. Protoc. Mouse Biol. 1 (2011), 71–83.
23. Wang, X., Ye, Y., Gong, H., Wu, J., Yuan, J., Wang, S., et al. The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice. J. Mol. Cell. Cardiol. 97 (2016), 180–190.
24. Ma, H., Guo, R., Yu, L., Zhang, Y., Ren, J., Aldehyde dehydrogenase 2 (ALDH2) rescues myocardial ischaemia/reperfusion injury: role of autophagy paradox and toxic aldehyde. Eur. Heart J. 32 (2011), 1025–1038.
25. Sreedhar, R., Arumugam, S., Thandavarayan, R.A., Giridharan, V.V., Karuppagounder, V., Pitchaimani, V., et al. Myocardial 14-3-3eta protein protects against mitochondria mediated apoptosis. Cell. Signal. 27 (2015), 770–776.
26. Chen, Z.W., Qian, J.Y., Ma, J.Y., Chang, S.F., Yun, H., Jin, H., et al. TNF-alpha-induced cardiomyocyte apoptosis contributes to cardiac dysfunction after coronary microembolization in mini-pigs. J. Cell. Mol. Med. 18 (2014), 1953–1963.
27. Cahill, T.J., Leo, V., Kelly, M., Stockenhuber, A., Kennedy, N.W., Bao, L., et al. Resistance of dynamin-related protein 1 oligomers to disassembly impairs mitophagy, resulting in myocardial inflammation and heart failure. J. Biol. Chem. 290 (2015), 25907–25919.
28. Grois, L., Hupf, J., Reinders, J., Schroder, J., Dietl, A., Schmid, P.M., et al. Combined inhibition of the renin-angiotensin system and neprilysin positively influences complex mitochondrial adaptations in progressive experimental heart failure. PLoS One, 12, 2017, e0169743.
29. von Lueder, T.G., Wang, B.H., Kompa, A.R., Huang, L., Webb, R., Jordaan, P., et al. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ. Heart Fail. 8 (2015), 71–78.
30. Givvimani, S., Munjal, C., Tyagi, N., Sen, U., Metreveli, N., Tyagi, S.C., Mitochondrial division/mitophagy inhibitor (Mdivi) ameliorates pressure overload induced heart failure. PLoS One, 7, 2012, e32388.
31. Gharanei, M., Hussain, A., Janneh, O., Maddock, H., Attenuation of doxorubicin-induced cardiotoxicity by mdivi-1: a mitochondrial division/mitophagy inhibitor. PLoS One, 8, 2013, e77713.
32. de Cavanagh, E.M., Inserra, F., Ferder, L., Angiotensin II blockade: a strategy to slow ageing by protecting mitochondria?. Cardiovasc. Res. 89 (2011), 31–40.
33. Lu, Y., Li, S., Wu, H., Bian, Z., Xu, J., Gu, C., et al. Beneficial effects of astragaloside IV against angiotensin II-induced mitochondrial dysfunction in rat vascular smooth muscle cells. Int. J. Mol. Med. 36 (2015), 1223–1232.
34. Lim, S., Lee, S.Y., Seo, H.H., Ham, O., Lee, C., Park, J.H., et al. Regulation of mitochondrial morphology by positive feedback interaction between PKCdelta and Drp1 in vascular smooth muscle cell. J. Cell. Biochem. 116 (2015), 648–660.